IL186431A - Methods and products for evaluating an immune response to a therapeutic protein - Google Patents

Methods and products for evaluating an immune response to a therapeutic protein

Info

Publication number
IL186431A
IL186431A IL186431A IL18643107A IL186431A IL 186431 A IL186431 A IL 186431A IL 186431 A IL186431 A IL 186431A IL 18643107 A IL18643107 A IL 18643107A IL 186431 A IL186431 A IL 186431A
Authority
IL
Israel
Prior art keywords
vla
antibody
binding
binding antibody
subject
Prior art date
Application number
IL186431A
Other languages
English (en)
Hebrew (he)
Other versions
IL186431A0 (en
Original Assignee
Biogen Idec Inc
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37023063&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL186431(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc, Elan Pharm Inc filed Critical Biogen Idec Inc
Publication of IL186431A0 publication Critical patent/IL186431A0/en
Publication of IL186431A publication Critical patent/IL186431A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
IL186431A 2005-04-04 2007-10-07 Methods and products for evaluating an immune response to a therapeutic protein IL186431A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66840405P 2005-04-04 2005-04-04
PCT/US2006/012493 WO2006107962A2 (en) 2005-04-04 2006-04-04 Methods and products for evaluating an immune response to a therapeutic protein

Publications (2)

Publication Number Publication Date
IL186431A0 IL186431A0 (en) 2008-01-20
IL186431A true IL186431A (en) 2012-03-29

Family

ID=37023063

Family Applications (1)

Application Number Title Priority Date Filing Date
IL186431A IL186431A (en) 2005-04-04 2007-10-07 Methods and products for evaluating an immune response to a therapeutic protein

Country Status (20)

Country Link
US (5) US8124350B2 (sr)
EP (4) EP2645106B1 (sr)
JP (3) JP2008537595A (sr)
CN (1) CN101351710B (sr)
AU (1) AU2006231511B2 (sr)
CA (2) CA3031792A1 (sr)
CY (2) CY1119412T1 (sr)
DK (2) DK3264094T3 (sr)
ES (3) ES2536915T5 (sr)
HK (2) HK1112059A1 (sr)
HR (2) HRP20171310T1 (sr)
HU (2) HUE052412T2 (sr)
IL (1) IL186431A (sr)
LT (2) LT3264094T (sr)
NZ (1) NZ562784A (sr)
PL (2) PL2645106T3 (sr)
PT (2) PT3264094T (sr)
RS (2) RS61229B1 (sr)
SI (2) SI3264094T1 (sr)
WO (1) WO2006107962A2 (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1485127E (pt) 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
DK3264094T3 (da) 2005-04-04 2020-11-23 Biogen Ma Inc Fremgangsmåder til evaluering af en immunrespons på et terapeutisk middel
JP2009528359A (ja) 2006-02-28 2009-08-06 エラン ファーマシューティカルズ，インコーポレイテッド ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
ES2532483T3 (es) 2007-12-15 2015-03-27 F. Hoffmann-La Roche Ag Ensayo de distinción
EP2240769A1 (en) * 2008-01-15 2010-10-20 Stichting Sanquin Bloedvoorziening Method and kits for detecting antibodies against therapeutic antibodies
AU2010303156B2 (en) 2009-10-11 2016-02-04 Biogen Ma Inc. Anti-VLA-4 related assays
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
HUE060312T2 (hu) 2010-01-11 2023-02-28 Biogen Ma Inc A JC vírus antitestek vizsgálata
JP5805190B2 (ja) 2010-08-19 2015-11-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 療法用モノクローナル抗体に結合する抗体の測定のためのアッセイ
LT3326645T (lt) * 2010-10-25 2020-08-10 Biogen Ma Inc. Alfa-4 integrino aktyvumo skirtumų, koreliuojant su skirtumais svcam ir (arba) smadcam lygiuose, nustatymo būdai
WO2012175201A1 (en) * 2011-06-20 2012-12-27 Cellzome Ag Methods for the characterization of antibodies
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
CN103439515B (zh) * 2013-08-14 2015-07-15 南方医科大学 一种抗体效价的检测方法
US20170059561A1 (en) * 2015-08-28 2017-03-02 The Florida International University Board Of Trustees Thermally Stable Electrochemical Sensor With Long Shelf-Life
EP3668544A1 (en) * 2017-08-15 2020-06-24 Progenity, Inc. Treatment of inflammatory disease using ingestible device to release immune modulator
CN112730846B (zh) * 2020-12-18 2023-12-15 安渡生物医药(杭州)有限公司 一种用于小鼠血样检测免疫复合物的方法

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3639350A (en) 1970-04-15 1972-02-01 Allied Chem Esterification of terephthalic acid with an alkylene glycol in the presence of guanidine or an alkyl guanidine
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4425112A (en) 1976-02-25 1984-01-10 The United States Of America As Represented By The Department Of Health And Human Services Flow-through centrifuge
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4235601A (en) 1979-01-12 1980-11-25 Thyroid Diagnostics, Inc. Test device and method for its use
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4517288A (en) 1981-01-23 1985-05-14 American Hospital Supply Corp. Solid phase system for ligand assay
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
CA1291031C (en) 1985-12-23 1991-10-22 Nikolaas C.J. De Jaeger Method for the detection of specific binding agents and their correspondingbindable substances
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5763262A (en) 1986-09-18 1998-06-09 Quidel Corporation Immunodiagnostic device
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
JPH0746107B2 (ja) 1987-04-27 1995-05-17 ユニリーバー・ナームローゼ・ベンノートシヤープ 検定法
US4943522A (en) 1987-06-01 1990-07-24 Quidel Lateral flow, non-bibulous membrane assay protocols
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US4818677A (en) 1987-12-03 1989-04-04 Monoclonal Antibodies, Inc. Membrane assay using focused sample application
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5221616A (en) 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5118630A (en) 1988-11-04 1992-06-02 Quidel Corporation Method for determining periodic infertility in females
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5084828A (en) 1989-09-29 1992-01-28 Healthtech Services Corp. Interactive medication delivery system
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
US5096837A (en) 1990-02-08 1992-03-17 Pacific Biotech, Inc. Immunochromatographic assay and method of using same
US5223220A (en) 1990-03-27 1993-06-29 Pacific Biotech, Inc. Solid phase immunoassay device and method of making same
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5118428A (en) 1990-11-13 1992-06-02 Quidel Method to remove red blood cells from whole blood samples
DE4139840B4 (de) 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
JP2868900B2 (ja) 1991-01-11 1999-03-10 クイデル コーポレイション ワンステップ側方流非吸収性アッセイ
US5225328A (en) 1991-05-30 1993-07-06 Quidel Corporation Stable alkaline phosphatase compositions with color enhancement and their use in assays
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5686315A (en) 1991-06-14 1997-11-11 Quidel Corporation Assay device for one step detection of analyte
EP0646179A4 (en) 1992-02-04 1996-10-02 Quidel Corp PROCESS FOR SIMPLIFIED EXTRACTION OF BACTERIAL ANTIGENS USING DEHYDRATE REAGENTS.
US5541069A (en) 1992-02-28 1996-07-30 Quidel Corporation Assay having improved dose response curve
ES2151902T3 (es) 1992-03-10 2001-01-16 Quidel Corp Medio de separacion de globulos rojos para dosificarlos mediante union especifica.
EP0678122B1 (en) 1993-01-12 1999-07-28 Biogen, Inc. Recombinant anti-vla4 antibody molecules
EP0682529B2 (en) 1993-02-09 2005-12-28 Biogen Idec MA, Inc. Antibody for the treatment of insulin dependent diabetes
US5415994A (en) 1993-08-02 1995-05-16 Quidel Corporation Lateral flow medical diagnostic assay device with sample extraction means
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US5434057A (en) 1994-02-02 1995-07-18 Quidel Corporation Sperm motility assay and devices
US5521102A (en) 1994-08-08 1996-05-28 Quidel Corporation Controlled sensitivity immunochromatographic assay
US5845255A (en) 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
US5712172A (en) 1995-05-18 1998-01-27 Wyntek Diagnostics, Inc. One step immunochromatographic device and method of use
US5804452A (en) 1995-04-27 1998-09-08 Quidel Corporation One step urine creatinine assays
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5786220A (en) 1995-04-28 1998-07-28 Quidel Corporation Assays and devices for distinguishing between normal and abnormal pregnancy
US6319676B1 (en) 1995-05-02 2001-11-20 Carter Wallace, Inc. Diagnostic detection device and method
US5773234A (en) 1995-08-07 1998-06-30 Quidel Corporation Method and device for chlamydia detection
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US6305377B1 (en) 1996-12-12 2001-10-23 Michael T. Portwood System and method for improving compliance of a medical regimen
US6306642B1 (en) 1997-11-24 2001-10-23 Quidel Corporation Enzyme substrate delivery and product registration in one step enzyme immunoassays
JPH11190734A (ja) * 1997-12-26 1999-07-13 Wakamoto Pharmaceut Co Ltd クローン病の検査方法および検査用キット
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
US6014631A (en) 1998-04-02 2000-01-11 Merck-Medco Managed Care, Llc Computer implemented patient medication review system and process for the managed care, health care and/or pharmacy industry
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US7171371B2 (en) 1999-09-03 2007-01-30 Smg Trust Method and system for providing pre and post operative support and care
DK1232392T3 (da) 1999-10-12 2003-07-28 Connex Ges Zur Optimierung Von Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring
US6612032B1 (en) 2000-01-31 2003-09-02 Lexmark International, Inc. Manufacturing method for ink jet pen
WO2001075449A1 (fr) 2000-03-30 2001-10-11 Nippon Kayaku Kabushiki Kaisha Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7018847B2 (en) 2000-05-05 2006-03-28 Pharmacia Diagnostics Ab Assay device with timer function
US6620626B1 (en) 2000-08-09 2003-09-16 Mission Research Corp. Antigen detection device and method
JP2002071694A (ja) * 2000-08-25 2002-03-12 Wakamoto Pharmaceut Co Ltd 炎症性腸疾患の検査方法及び検査用キット
AU2002210384B2 (en) 2000-10-17 2006-10-19 Besst-Test Aps Assay for directly detecting a RS virus related biological cell in a body fluid sample
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US6485460B2 (en) 2001-01-12 2002-11-26 Bracco Diagnostics, Inc. Tamper evident syringe barrel
US7291477B2 (en) 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
US20030040027A1 (en) * 2001-08-16 2003-02-27 Gerd Ritter Method for determining protein component in a biological sample
US7205159B2 (en) 2001-08-20 2007-04-17 Proteome Systems Intellectual Property Pty Ltd. Diagnostic testing process and apparatus
PT1485127E (pt) * 2002-02-25 2011-09-07 Elan Pharm Inc Administração de agentes para o tratamento de inflamação
AU2003270643A1 (en) * 2002-09-12 2004-04-30 The Regents Of The University Of California Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence
US20040203072A1 (en) * 2002-11-08 2004-10-14 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
ZA200600798B (en) * 2003-07-29 2007-06-27 Genentech Inc Assay for human anti CD20 antibodies and uses therefor
US7238538B2 (en) 2003-09-19 2007-07-03 Freitag Helmut E Chromatographic assay device and methods
EP1664781B1 (en) 2003-09-22 2013-05-08 Quidel Corporation Devices for the detection of multiple analytes in a sample
JP4672263B2 (ja) 2004-01-27 2011-04-20 デンカ生研株式会社 簡便な検出法、検出装置及び検出キットとその製法
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US20050283385A1 (en) 2004-06-21 2005-12-22 The Permanente Medical Group, Inc. Individualized healthcare management system
US8445293B2 (en) 2005-02-09 2013-05-21 Rapid Pathogen Screening, Inc. Method to increase specificity and/or accuracy of lateral flow immunoassays
US7972775B2 (en) 2005-03-03 2011-07-05 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing Natalizumab treatment
DK3264094T3 (da) 2005-04-04 2020-11-23 Biogen Ma Inc Fremgangsmåder til evaluering af en immunrespons på et terapeutisk middel
US20060246513A1 (en) 2005-05-02 2006-11-02 Bohannon Robert C Method and device to detect the presence of analytes in a sample
JP2009528359A (ja) 2006-02-28 2009-08-06 エラン ファーマシューティカルズ，インコーポレイテッド ナタリズマブを用いて炎症性疾患および自己免疫性疾患を治療する方法
JP2009531304A (ja) 2006-02-28 2009-09-03 エラン ファーマシューティカルズ，インコーポレイテッド α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
SG170058A1 (en) 2006-03-03 2011-04-29 Elan Pharm Inc Methods of treating inflammatory and autoimmune diseases with natalizumab
JP3157356U (ja) 2006-07-26 2010-02-18 インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 生物学的試料用の分析装置
US7704702B2 (en) 2006-08-10 2010-04-27 Inverness Medical Switzerland Gmbh Test strip for lateral flow assays
EP2089515A4 (en) 2006-11-16 2011-02-23 Novavax Inc VIRUSUAL PARTICLES OF RESPIRATORY SYNZYTIAL VIRUS
EP1933140B1 (en) 2006-12-11 2011-08-17 AraGen Biotechnology Co. Ltd. Antibody detection method involving an oligonucleotide enhanced collodial gold signal
WO2009032174A1 (en) 2007-08-30 2009-03-12 President And Fellows Of Harvard College Bio-matrix stretcher
HUE060312T2 (hu) 2010-01-11 2023-02-28 Biogen Ma Inc A JC vírus antitestek vizsgálata

Also Published As

Publication number Publication date
HUE052412T2 (hu) 2021-04-28
HK1245884A1 (zh) 2018-08-31
CN101351710A (zh) 2009-01-21
EP1872136B1 (en) 2015-02-18
EP1872136A2 (en) 2008-01-02
EP2645106A3 (en) 2013-10-09
JP2008537595A (ja) 2008-09-18
PT3264094T (pt) 2020-11-24
SI3264094T1 (sl) 2021-04-30
AU2006231511B2 (en) 2012-02-16
DK2645106T3 (en) 2017-10-02
DK3264094T3 (da) 2020-11-23
EP1872136B9 (en) 2023-02-08
ES2640295T3 (es) 2017-11-02
US20150071917A1 (en) 2015-03-12
WO2006107962A3 (en) 2007-03-08
AU2006231511A1 (en) 2006-10-12
ES2536915T5 (es) 2023-03-01
JP2014197032A (ja) 2014-10-16
HUE034318T2 (en) 2018-02-28
NZ562784A (en) 2010-07-30
US9709575B2 (en) 2017-07-18
EP2645106B1 (en) 2017-06-14
JP2012008146A (ja) 2012-01-12
ES2536915T3 (es) 2015-05-29
LT2645106T (lt) 2017-09-11
CA2603481A1 (en) 2006-10-12
EP1872136B2 (en) 2022-11-16
WO2006107962A8 (en) 2008-01-24
US20090176256A1 (en) 2009-07-09
ES2833948T3 (es) 2021-06-16
JP6044904B2 (ja) 2016-12-14
CY1119412T1 (el) 2018-03-07
US20120195884A1 (en) 2012-08-02
IL186431A0 (en) 2008-01-20
US20210025900A1 (en) 2021-01-28
US10705095B2 (en) 2020-07-07
HK1112059A1 (en) 2008-08-22
PL3264094T3 (pl) 2021-04-19
US8124350B2 (en) 2012-02-28
US20180088127A1 (en) 2018-03-29
WO2006107962A2 (en) 2006-10-12
SI2645106T1 (en) 2018-01-31
CN101351710B (zh) 2013-06-05
US8871449B2 (en) 2014-10-28
PT2645106T (pt) 2017-09-18
EP3264094A1 (en) 2018-01-03
WO2006107962A9 (en) 2007-04-19
EP3796003A1 (en) 2021-03-24
EP2645106A2 (en) 2013-10-02
CY1123750T1 (el) 2022-03-24
HRP20171310T1 (hr) 2017-12-15
CA2603481C (en) 2019-03-12
CA3031792A1 (en) 2006-10-12
US11686734B2 (en) 2023-06-27
EP3264094B1 (en) 2020-08-19
RS61229B1 (sr) 2021-01-29
HRP20201840T1 (hr) 2021-04-02
LT3264094T (lt) 2021-04-12
PL2645106T3 (pl) 2017-11-30
RS56418B1 (sr) 2018-01-31

Similar Documents

Publication Publication Date Title
US11686734B2 (en) Methods and products for evaluating an immune response to a therapeutic protein
EP3237004A1 (en) Predicting outcome of treatment with an anti- 4 7 integrin antibody
EP2828292B1 (en) Jcv neutralizing antibodies
EP2828284B1 (en) Jcv neutralizing antibodies
AU2012202823B2 (en) Methods and Products for Evaluating an Immune Response to a Therapeutic Protein
WO2023148165A1 (en) Method for diagnosing collagen degradatation associated disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed